speb/financial-data huggingface dataset:
PCQ.V income_statement (quarterly, 2025-12-31) — General And Administrative Expense: 660900.00
PCQ.V balance_sheet (annual, 2025-12-31) — Invested Capital: -2477620.00
PCQ.V balance_sheet (quarterly, 2025-12-31) — Invested Capital: -2477620.00
PCQ.V cash_flow (annual, 2025-12-31) — Issuance Of Capital Stock: 150000.00
PCQ.V cash_flow (quarterly, 2025-12-31) — Issuance Of Capital Stock: 0.00
PCQ.V balance_sheet (annual, 2025-12-31) — Long Term Debt: 14386.00
PCQ.V balance_sheet (quarterly, 2025-12-31) — Long Term Debt: 14386.00
PCQ.V balance_sheet (annual, 2025-12-31) — Long Term Debt And Capital Lease Obligation: 14386.00
PCQ.V balance_sheet (quarterly, 2025-12-31) — Long Term Debt And Capital Lease Obligation: 14386.00
PCQ.V cash_flow (annual, 2025-12-31) — Long Term Debt Payments: -7067.00
PCQ.V cash_flow (quarterly, 2025-12-31) — Long Term Debt Payments: -1390.00
PCQ.V cash_flow (annual, 2025-12-31) — Net Common Stock Issuance: 150000.00
PCQ.V cash_flow (quarterly, 2025-12-31) — Net Common Stock Issuance: 0.00
PCQ.V cash_flow (annual, 2025-12-31) — Net Foreign Currency Exchange Gain Loss: -16529.00
PCQ.V cash_flow (quarterly, 2025-12-31) — Net Foreign Currency Exchange Gain Loss: -5203.00
PCQ.V income_statement (annual, 2025-12-31) — Net Income: -1046401.00
PCQ.V income_statement (quarterly, 2025-12-31) — Net Income: -649728.00
PCQ.V income_statement (annual, 2025-12-31) — Net Income Common Stockholders: -1046401.00
PCQ.V income_statement (quarterly, 2025-12-31) — Net Income Common Stockholders: -649728.00
PCQ.V income_statement (annual, 2025-12-31) — Net Income Continuous Operations: -1046401.00
PCQ.V income_statement (quarterly, 2025-12-31) — Net Income Continuous Operations: -649728.00
PCQ.V income_statement (annual, 2025-12-31) — Net Income From Continuing And Discontinued Operation: -1046401.00
PCQ.V income_statement (quarterly, 2025-12-31) — Net Income From Continuing And Discontinued Operation: -649728.00
PCQ.V income_statement (annual, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: -1046401.00
PCQ.V income_statement (quarterly, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: -649728.00
PCQ.V cash_flow (annual, 2025-12-31) — Net Income From Continuing Operations: -1046401.00
PCQ.V cash_flow (quarterly, 2025-12-31) — Net Income From Continuing Operations: -649728.00
PCQ.V income_statement (annual, 2025-12-31) — Net Income Including Noncontrolling Interests: -1046401.00
PCQ.V income_statement (quarterly, 2025-12-31) — Net Income Including Noncontrolling Interests: -649728.00
PCQ.V cash_flow (annual, 2025-12-31) — Net Issuance Payments Of Debt: -7067.00
PCQ.V cash_flow (quarterly, 2025-12-31) — Net Issuance Payments Of Debt: -1390.00
PCQ.V cash_flow (annual, 2025-12-31) — Net Long Term Debt Issuance: -7067.00
PCQ.V cash_flow (quarterly, 2025-12-31) — Net Long Term Debt Issuance: -1390.00
PCQ.V balance_sheet (annual, 2025-12-31) — Net Tangible Assets: -2492006.00
PCQ.V balance_sheet (quarterly, 2025-12-31) — Net Tangible Assets: -2492006.00
PCQ.V income_statement (annual, 2025-12-31) — Normalized EBITDA: -1229312.00
PCQ.V income_statement (quarterly, 2025-12-31) — Normalized EBITDA: -787389.00
PCQ.V income_statement (annual, 2025-12-31) — Normalized Income: -1115557.00
PCQ.V income_statement (quarterly, 2025-12-31) — Normalized Income: -673199.00
PCQ.V cash_flow (annual, 2025-12-31) — Operating Cash Flow: -16832.00
PCQ.V cash_flow (quarterly, 2025-12-31) — Operating Cash Flow: 96060.00
PCQ.V cash_flow (annual, 2025-12-31) — Operating Gains Losses: -16529.00
PCQ.V cash_flow (quarterly, 2025-12-31) — Operating Gains Losses: -5203.00
PCQ.V income_statement (annual, 2025-12-31) — Operating Income: -1160156.00
PCQ.V income_statement (quarterly, 2025-12-31) — Operating Income: -712745.00
PCQ.V income_statement (annual, 2025-12-31) — Operating Revenue: 0.00
PCQ.V income_statement (quarterly, 2025-12-31) — Operating Revenue: 0.00
PCQ.V balance_sheet (annual, 2025-12-31) — Ordinary Shares Number: 141889927.00
PCQ.V balance_sheet (quarterly, 2025-12-31) — Ordinary Shares Number: 141889927.00
PCQ.V balance_sheet (annual, 2025-12-31) — Other Equity Interest: 153140.00
PCQ.V balance_sheet (quarterly, 2025-12-31) — Other Equity Interest: 153140.00
PCQ.V income_statement (annual, 2025-12-31) — Other Gand A: 663046.00
PCQ.V income_statement (quarterly, 2025-12-31) — Other Gand A: 440491.00
PCQ.V income_statement (annual, 2025-12-31) — Other Income Expense: 113755.00
PCQ.V income_statement (quarterly, 2025-12-31) — Other Income Expense: 62582.00
PCQ.V cash_flow (annual, 2025-12-31) — Other Non Cash Items: -32957.00
PCQ.V cash_flow (quarterly, 2025-12-31) — Other Non Cash Items: -29172.00
PCQ.V income_statement (annual, 2025-12-31) — Other Non Operating Income Expenses: 44599.00
PCQ.V income_statement (quarterly, 2025-12-31) — Other Non Operating Income Expenses: 39111.00
PCQ.V income_statement (annual, 2025-12-31) — Other Operating Expenses: 95354.00
PCQ.V income_statement (quarterly, 2025-12-31) — Other Operating Expenses: 50793.00
PCQ.V balance_sheet (annual, 2025-12-31) — Other Receivables: 9131.00
PCQ.V balance_sheet (quarterly, 2025-12-31) — Other Receivables: 9131.00
PCQ.V balance_sheet (annual, 2025-12-31) — Payables: 216870.00
PCQ.V balance_sheet (quarterly, 2025-12-31) — Payables: 216870.00
PCQ.V balance_sheet (annual, 2025-12-31) — Payables And Accrued Expenses: 2300431.00
PCQ.V balance_sheet (quarterly, 2025-12-31) — Payables And Accrued Expenses: 2300431.00
PCQ.V income_statement (annual, 2025-12-31) — Pretax Income: -1046401.00
PCQ.V income_statement (quarterly, 2025-12-31) — Pretax Income: -649728.00
PCQ.V balance_sheet (annual, 2025-12-31) — Receivables: 9131.00
PCQ.V balance_sheet (quarterly, 2025-12-31) — Receivables: 9131.00
PCQ.V cash_flow (annual, 2025-12-31) — Repayment Of Debt: -7067.00
PCQ.V cash_flow (quarterly, 2025-12-31) — Repayment Of Debt: -1390.00
PCQ.V balance_sheet (annual, 2025-12-31) — Retained Earnings: -14407171.00
PCQ.V balance_sheet (quarterly, 2025-12-31) — Retained Earnings: -14407171.00
PCQ.V income_statement (annual, 2025-12-31) — Salaries And Wages: 397604.00
PCQ.V income_statement (quarterly, 2025-12-31) — Salaries And Wages: 220409.00
PCQ.V income_statement (annual, 2025-12-31) — Selling And Marketing Expense: 4152.00
PCQ.V income_statement (quarterly, 2025-12-31) — Selling And Marketing Expense: 1052.00
PCQ.V income_statement (annual, 2025-12-31) — Selling General And Administration: 1064802.00
PCQ.V income_statement (quarterly, 2025-12-31) — Selling General And Administration: 661952.00
PCQ.V balance_sheet (annual, 2025-12-31) — Share Issued: 141889927.00
PCQ.V balance_sheet (quarterly, 2025-12-31) — Share Issued: 141889927.00
PCQ.V cash_flow (annual, 2025-12-31) — Stock Based Compensation: 397604.00
PCQ.V cash_flow (quarterly, 2025-12-31) — Stock Based Compensation: 220409.00
PCQ.V balance_sheet (annual, 2025-12-31) — Stockholders Equity: -2492006.00
PCQ.V balance_sheet (quarterly, 2025-12-31) — Stockholders Equity: -2492006.00
PCQ.V balance_sheet (annual, 2025-12-31) — Tangible Book Value: -2492006.00
PCQ.V balance_sheet (quarterly, 2025-12-31) — Tangible Book Value: -2492006.00
PCQ.V income_statement (annual, 2025-12-31) — Tax Effect Of Unusual Items: 0.00
PCQ.V income_statement (quarterly, 2025-12-31) — Tax Effect Of Unusual Items: 0.00
PCQ.V income_statement (annual, 2025-12-31) — Tax Rate For Calcs: 0.00
PCQ.V income_statement (quarterly, 2025-12-31) — Tax Rate For Calcs: 0.00
PCQ.V balance_sheet (annual, 2025-12-31) — Total Assets: 160274.00
PCQ.V balance_sheet (quarterly, 2025-12-31) — Total Assets: 160274.00
PCQ.V balance_sheet (annual, 2025-12-31) — Total Capitalization: -2477620.00
PCQ.V balance_sheet (quarterly, 2025-12-31) — Total Capitalization: -2477620.00
PCQ.V balance_sheet (annual, 2025-12-31) — Total Debt: 20147.00
PCQ.V balance_sheet (quarterly, 2025-12-31) — Total Debt: 20147.00
PCQ.V balance_sheet (annual, 2025-12-31) — Total Equity Gross Minority Interest: -2492006.00
PCQ.V balance_sheet (quarterly, 2025-12-31) — Total Equity Gross Minority Interest: -2492006.00
PCQ.V income_statement (annual, 2025-12-31) — Total Expenses: 1160156.00
PCQ.V income_statement (quarterly, 2025-12-31) — Total Expenses: 712745.00
PCQ.V balance_sheet (annual, 2025-12-31) — Total Liabilities Net Minority Interest: 2652280.00
PCQ.V balance_sheet (quarterly, 2025-12-31) — Total Liabilities Net Minority Interest: 2652280.00
PCQ.V balance_sheet (annual, 2025-12-31) — Total Non Current Assets: 0.00
PCQ.V balance_sheet (quarterly, 2025-12-31) — Total Non Current Assets: 0.00
PCQ.V balance_sheet (annual, 2025-12-31) — Total Non Current Liabilities Net Minority Interest: 14386.00
PCQ.V balance_sheet (quarterly, 2025-12-31) — Total Non Current Liabilities Net Minority Interest: 14386.00
PCQ.V income_statement (annual, 2025-12-31) — Total Operating Income As Reported: -1160156.00
PCQ.V income_statement (quarterly, 2025-12-31) — Total Operating Income As Reported: -712745.00
PCQ.V income_statement (annual, 2025-12-31) — Total Unusual Items: 69156.00
PCQ.V income_statement (quarterly, 2025-12-31) — Total Unusual Items: 23471.00
PCQ.V income_statement (annual, 2025-12-31) — Total Unusual Items Excluding Goodwill: 69156.00
PCQ.V income_statement (quarterly, 2025-12-31) — Total Unusual Items Excluding Goodwill: 23471.00
PCQ.V balance_sheet (annual, 2025-12-31) — Working Capital: -2477620.00
PCQ.V balance_sheet (quarterly, 2025-12-31) — Working Capital: -2477620.00
PCQ.V income_statement (quarterly, 2026-03-31) — +Operating Expense: 108988.00
PCQ.V income_statement (quarterly, 2026-03-31) — +Total Revenue: 0.00
PCQ.V balance_sheet (quarterly, 2026-03-31) — Accounts Payable: 50401.00
PCQ.V balance_sheet (quarterly, 2026-03-31) — Additional Paid In Capital: 843500.00
PCQ.V income_statement (quarterly, 2026-03-31) — Basic Average Shares: 144261557.00
PCQ.V income_statement (quarterly, 2026-03-31) — Basic EPS: 0.00
PCQ.V cash_flow (quarterly, 2026-03-31) — Beginning Cash Position: 151143.00
PCQ.V balance_sheet (quarterly, 2026-03-31) — Capital Stock: 11150120.00
PCQ.V balance_sheet (quarterly, 2026-03-31) — Cash And Cash Equivalents: 198835.00
PCQ.V balance_sheet (quarterly, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 198835.00
PCQ.V balance_sheet (quarterly, 2026-03-31) — Cash Equivalents: 10000.00
PCQ.V balance_sheet (quarterly, 2026-03-31) — Cash Financial: 188835.00
PCQ.V cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Financing Activities: 480753.00
PCQ.V cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Operating Activities: -433061.00
PCQ.V cash_flow (quarterly, 2026-03-31) — Change In Payables And Accrued Expense: -333263.00
PCQ.V cash_flow (quarterly, 2026-03-31) — Change In Receivables: 9131.00
PCQ.V cash_flow (quarterly, 2026-03-31) — Change In Working Capital: -324132.00
PCQ.V cash_flow (quarterly, 2026-03-31) — Changes In Cash: 47692.00
PCQ.V balance_sheet (quarterly, 2026-03-31) — Common Stock: 11150120.00
PCQ.V balance_sheet (quarterly, 2026-03-31) — Common Stock Equity: -2194093.00
PCQ.V cash_flow (quarterly, 2026-03-31) — Common Stock Issuance: 415600.00
PCQ.V balance_sheet (quarterly, 2026-03-31) — Current Accrued Expenses: 1916767.00
PCQ.V balance_sheet (quarterly, 2026-03-31) — Current Assets: 198835.00
PCQ.V balance_sheet (quarterly, 2026-03-31) — Current Debt And Capital Lease Obligation: 6041.00
PCQ.V balance_sheet (quarterly, 2026-03-31) — Current Deferred Liabilities: 407035.00
PCQ.V balance_sheet (quarterly, 2026-03-31) — Current Liabilities: 2380244.00
PCQ.V income_statement (quarterly, 2026-03-31) — Diluted Average Shares: 144261557.00
PCQ.V income_statement (quarterly, 2026-03-31) — Diluted EPS: 0.00
PCQ.V income_statement (quarterly, 2026-03-31) — Diluted NI Availto Com Stockholders: -117687.00
PCQ.V income_statement (quarterly, 2026-03-31) — EBIT: -117687.00
PCQ.V income_statement (quarterly, 2026-03-31) — EBITDA: -117687.00
PCQ.V cash_flow (quarterly, 2026-03-31) — End Cash Position: 198835.00
PCQ.V cash_flow (quarterly, 2026-03-31) — Financing Cash Flow: 480753.00
PCQ.V cash_flow (quarterly, 2026-03-31) — Free Cash Flow: -433061.00
PCQ.V income_statement (quarterly, 2026-03-31) — Gain On Sale Of Security: -8122.00
PCQ.V income_statement (quarterly, 2026-03-31) — General And Administrative Expense: 107807.00
PCQ.V income_statement (quarterly, 2026-03-31) — Interest Expense: 0.00
PCQ.V income_statement (quarterly, 2026-03-31) — Interest Expense Non Operating: 0.00
PCQ.V balance_sheet (quarterly, 2026-03-31) — Invested Capital: -2181409.00
PCQ.V cash_flow (quarterly, 2026-03-31) — Issuance Of Capital Stock: 415600.00
PCQ.V balance_sheet (quarterly, 2026-03-31) — Long Term Debt: 12684.00
PCQ.V balance_sheet (quarterly, 2026-03-31) — Long Term Debt And Capital Lease Obligation: 12684.00
PCQ.V cash_flow (quarterly, 2026-03-31) — Long Term Debt Payments: -1892.00
PCQ.V cash_flow (quarterly, 2026-03-31) — Net Common Stock Issuance: 415600.00
PCQ.V cash_flow (quarterly, 2026-03-31) — Net Foreign Currency Exchange Gain Loss: 8288.00
PCQ.V income_statement (quarterly, 2026-03-31) — Net Income: -117687.00
PCQ.V income_statement (quarterly, 2026-03-31) — Net Income Common Stockholders: -117687.00
PCQ.V income_statement (quarterly, 2026-03-31) — Net Income Continuous Operations: -117687.00
PCQ.V income_statement (quarterly, 2026-03-31) — Net Income From Continuing And Discontinued Operation: -117687.00
PCQ.V income_statement (quarterly, 2026-03-31) — Net Income From Continuing Operation Net Minority Interest: -117687.00
PCQ.V cash_flow (quarterly, 2026-03-31) — Net Income From Continuing Operations: -117687.00
PCQ.V income_statement (quarterly, 2026-03-31) — Net Income Including Noncontrolling Interests: -117687.00
PCQ.V income_statement (quarterly, 2026-03-31) — Net Interest Income: 0.00
PCQ.V cash_flow (quarterly, 2026-03-31) — Net Issuance Payments Of Debt: -1892.00
PCQ.V cash_flow (quarterly, 2026-03-31) — Net Long Term Debt Issuance: -1892.00
PCQ.V income_statement (quarterly, 2026-03-31) — Net Non Operating Interest Income Expense: 0.00
PCQ.V cash_flow (quarterly, 2026-03-31) — Net Other Financing Charges: 67045.00
PCQ.V balance_sheet (quarterly, 2026-03-31) — Net Tangible Assets: -2194093.00
PCQ.V income_statement (quarterly, 2026-03-31) — Normalized EBITDA: -109565.00
PCQ.V income_statement (quarterly, 2026-03-31) — Normalized Income: -109565.00
PCQ.V cash_flow (quarterly, 2026-03-31) — Operating Cash Flow: -433061.00
PCQ.V cash_flow (quarterly, 2026-03-31) — Operating Gains Losses: 8288.00
PCQ.V income_statement (quarterly, 2026-03-31) — Operating Income: -108988.00
PCQ.V income_statement (quarterly, 2026-03-31) — Operating Revenue: 0.00
PCQ.V balance_sheet (quarterly, 2026-03-31) — Ordinary Shares Number: 147084927.00
PCQ.V balance_sheet (quarterly, 2026-03-31) — Other Equity Interest: 337145.00
PCQ.V income_statement (quarterly, 2026-03-31) — Other Gand A: 107807.00
PCQ.V income_statement (quarterly, 2026-03-31) — Other Income Expense: -8699.00
PCQ.V cash_flow (quarterly, 2026-03-31) — Other Non Cash Items: 470.00
PCQ.V income_statement (quarterly, 2026-03-31) — Other Non Operating Income Expenses: -577.00
PCQ.V balance_sheet (quarterly, 2026-03-31) — Payables: 50401.00
PCQ.V balance_sheet (quarterly, 2026-03-31) — Payables And Accrued Expenses: 1967168.00
PCQ.V income_statement (quarterly, 2026-03-31) — Pretax Income: -117687.00
PCQ.V balance_sheet (quarterly, 2026-03-31) — Receivables: 0.00
PCQ.V cash_flow (quarterly, 2026-03-31) — Repayment Of Debt: -1892.00
PCQ.V balance_sheet (quarterly, 2026-03-31) — Retained Earnings: -14524858.00
PCQ.V income_statement (quarterly, 2026-03-31) — Selling And Marketing Expense: 1181.00
PCQ.V income_statement (quarterly, 2026-03-31) — Selling General And Administration: 108988.00
PCQ.V balance_sheet (quarterly, 2026-03-31) — Share Issued: 147084927.00
PCQ.V balance_sheet (quarterly, 2026-03-31) — Stockholders Equity: -2194093.00
PCQ.V balance_sheet (quarterly, 2026-03-31) — Tangible Book Value: -2194093.00
PCQ.V income_statement (quarterly, 2026-03-31) — Tax Effect Of Unusual Items: 0.00
PCQ.V income_statement (quarterly, 2026-03-31) — Tax Rate For Calcs: 0.00
PCQ.V balance_sheet (quarterly, 2026-03-31) — Total Assets: 198835.00
PCQ.V balance_sheet (quarterly, 2026-03-31) — Total Capitalization: -2181409.00
PCQ.V balance_sheet (quarterly, 2026-03-31) — Total Debt: 18725.00
PCQ.V balance_sheet (quarterly, 2026-03-31) — Total Equity Gross Minority Interest: -2194093.00
PCQ.V income_statement (quarterly, 2026-03-31) — Total Expenses: 108988.00
PCQ.V balance_sheet (quarterly, 2026-03-31) — Total Liabilities Net Minority Interest: 2392928.00
PCQ.V balance_sheet (quarterly, 2026-03-31) — Total Non Current Assets: 0.00
PCQ.V balance_sheet (quarterly, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 12684.00
PCQ.V income_statement (quarterly, 2026-03-31) — Total Operating Income As Reported: -108988.00
PCQ.V income_statement (quarterly, 2026-03-31) — Total Unusual Items: -8122.00
PCQ.V income_statement (quarterly, 2026-03-31) — Total Unusual Items Excluding Goodwill: -8122.00
PCQ.V balance_sheet (quarterly, 2026-03-31) — Working Capital: -2181409.00
PCRX cash_flow (annual, 2021-12-31) — Change In Other Current Liabilities: -104000.00
PCRX cash_flow (annual, 2021-12-31) — Change In Other Working Capital: 125000.00
PCRX balance_sheet (annual, 2021-12-31) — Current Debt: 374700000.00
PCRX cash_flow (annual, 2021-12-31) — Gain Loss On Investment Securities: 2673000.00
PCRX cash_flow (annual, 2021-12-31) — Gain Loss On Sale Of PPE: -10000.00
PCRX cash_flow (annual, 2021-12-31) — Income Tax Paid Supplemental Data: 3221000.00
PCRX balance_sheet (annual, 2021-12-31) — Income Tax Payable: 429000.00
PCRX balance_sheet (annual, 2021-12-31) — Investmentin Financial Assets: 0.00
PCRX balance_sheet (annual, 2021-12-31) — Investments And Advances: 0.00
PCRX cash_flow (annual, 2021-12-31) — Net Other Investing Changes: -4000000.00
PCRX cash_flow (annual, 2021-12-31) — Net Short Term Debt Issuance: 363750000.00
PCRX balance_sheet (annual, 2021-12-31) — Non Current Deferred Liabilities: 10125000.00
PCRX balance_sheet (annual, 2021-12-31) — Non Current Deferred Revenue: 10125000.00
PCRX balance_sheet (annual, 2021-12-31) — Other Current Borrowings: 374700000.00
PCRX balance_sheet (annual, 2021-12-31) — Other Investments: 21987000.00
PCRX balance_sheet (annual, 2021-12-31) — Prepaid Assets: 14771000.00
PCRX cash_flow (annual, 2021-12-31) — Short Term Debt Issuance: 363750000.00
PCRX balance_sheet (annual, 2021-12-31) — Total Tax Payable: 429000.00
PCRX income_statement (annual, 2022-12-31) — +Operating Expense: 407504000.00
PCRX income_statement (annual, 2022-12-31) — +Total Revenue: 666823000.00
PCRX balance_sheet (annual, 2022-12-31) — Accounts Payable: 15220000.00
PCRX balance_sheet (annual, 2022-12-31) — Accounts Receivable: 98397000.00
PCRX balance_sheet (annual, 2022-12-31) — Accumulated Depreciation: -117480000.00
PCRX balance_sheet (annual, 2022-12-31) — Additional Paid In Capital: 924095000.00
PCRX income_statement (annual, 2022-12-31) — Amortization: 57288000.00
PCRX income_statement (annual, 2022-12-31) — Amortization Of Intangibles Income Statement: 57288000.00
PCRX cash_flow (annual, 2022-12-31) — Asset Impairment Charge: 36134000.00
PCRX balance_sheet (annual, 2022-12-31) — Available For Sale Securities: 37209000.00
PCRX income_statement (annual, 2022-12-31) — Average Dilution Earnings: 0.00
PCRX income_statement (annual, 2022-12-31) — Basic Average Shares: 45521000.00
PCRX income_statement (annual, 2022-12-31) — Basic EPS: 0.35
PCRX cash_flow (annual, 2022-12-31) — Beginning Cash Position: 585578000.00
PCRX cash_flow (annual, 2022-12-31) — Capital Expenditure: -30076000.00
PCRX balance_sheet (annual, 2022-12-31) — Capital Lease Obligations: 73923000.00
PCRX balance_sheet (annual, 2022-12-31) — Capital Stock: 46000.00
PCRX balance_sheet (annual, 2022-12-31) — Cash And Cash Equivalents: 104139000.00
PCRX balance_sheet (annual, 2022-12-31) — Cash Cash Equivalents And Short Term Investments: 288651000.00
PCRX cash_flow (annual, 2022-12-31) — Cash Flow From Continuing Financing Activities: -401528000.00
PCRX cash_flow (annual, 2022-12-31) — Cash Flow From Continuing Investing Activities: -225185000.00
PCRX cash_flow (annual, 2022-12-31) — Cash Flow From Continuing Operating Activities: 145274000.00
PCRX cash_flow (annual, 2022-12-31) — Change In Account Payable: 6272000.00
PCRX cash_flow (annual, 2022-12-31) — Change In Accrued Expense: -19857000.00
PCRX cash_flow (annual, 2022-12-31) — Change In Inventory: 2486000.00
PCRX cash_flow (annual, 2022-12-31) — Change In Other Current Liabilities: -556000.00
PCRX cash_flow (annual, 2022-12-31) — Change In Payable: 6272000.00
PCRX cash_flow (annual, 2022-12-31) — Change In Payables And Accrued Expense: -13585000.00
PCRX cash_flow (annual, 2022-12-31) — Change In Prepaid Assets: -2699000.00
PCRX cash_flow (annual, 2022-12-31) — Change In Receivables: -2079000.00
PCRX cash_flow (annual, 2022-12-31) — Change In Working Capital: -16433000.00
PCRX cash_flow (annual, 2022-12-31) — Changes In Account Receivables: -2079000.00
PCRX cash_flow (annual, 2022-12-31) — Changes In Cash: -481439000.00
PCRX balance_sheet (annual, 2022-12-31) — Common Stock: 46000.00
PCRX balance_sheet (annual, 2022-12-31) — Common Stock Equity: 775010000.00
PCRX cash_flow (annual, 2022-12-31) — Common Stock Payments: 0.00
PCRX balance_sheet (annual, 2022-12-31) — Construction In Progress: 103226000.00
PCRX income_statement (annual, 2022-12-31) — Cost Of Revenue: 199295000.00
PCRX balance_sheet (annual, 2022-12-31) — Current Accrued Expenses: 63587000.00
PCRX balance_sheet (annual, 2022-12-31) — Current Assets: 498334000.00
PCRX balance_sheet (annual, 2022-12-31) — Current Capital Lease Obligation: 9121000.00
PCRX balance_sheet (annual, 2022-12-31) — Current Debt: 33648000.00
PCRX balance_sheet (annual, 2022-12-31) — Current Debt And Capital Lease Obligation: 42769000.00
PCRX balance_sheet (annual, 2022-12-31) — Current Liabilities: 147774000.00
PCRX cash_flow (annual, 2022-12-31) — Deferred Income Tax: -7945000.00
PCRX cash_flow (annual, 2022-12-31) — Deferred Tax: -7945000.00
PCRX cash_flow (annual, 2022-12-31) — Depreciation Amortization Depletion: 91501000.00
PCRX income_statement (annual, 2022-12-31) — Depreciation Amortization Depletion Income Statement: 57288000.00
PCRX cash_flow (annual, 2022-12-31) — Depreciation And Amortization: 91501000.00
PCRX income_statement (annual, 2022-12-31) — Depreciation And Amortization In Income Statement: 57288000.00
PCRX income_statement (annual, 2022-12-31) — Diluted Average Shares: 46538000.00
PCRX income_statement (annual, 2022-12-31) — Diluted EPS: 0.34
PCRX income_statement (annual, 2022-12-31) — Diluted NI Availto Com Stockholders: 15909000.00
PCRX income_statement (annual, 2022-12-31) — EBIT: 48878000.00
PCRX income_statement (annual, 2022-12-31) — EBITDA: 140379000.00
PCRX cash_flow (annual, 2022-12-31) — End Cash Position: 104139000.00
PCRX cash_flow (annual, 2022-12-31) — Financing Cash Flow: -401528000.00
PCRX balance_sheet (annual, 2022-12-31) — Finished Goods: 27400000.00
PCRX cash_flow (annual, 2022-12-31) — Free Cash Flow: 115198000.00
PCRX cash_flow (annual, 2022-12-31) — Gain Loss On Investment Securities: 92000.00
PCRX cash_flow (annual, 2022-12-31) — Gain Loss On Sale Of PPE: 193000.00
PCRX balance_sheet (annual, 2022-12-31) — Gains Losses Not Affecting Retained Earnings: -380000.00
PCRX income_statement (annual, 2022-12-31) — General And Administrative Expense: 109520000.00
PCRX balance_sheet (annual, 2022-12-31) — Goodwill: 163243000.00
PCRX balance_sheet (annual, 2022-12-31) — Goodwill And Other Intangible Assets: 703789000.00
PCRX balance_sheet (annual, 2022-12-31) — Gross PPE: 371869000.00
PCRX income_statement (annual, 2022-12-31) — Gross Profit: 467528000.00
PCRX income_statement (annual, 2022-12-31) — Impairment Of Capital Assets: 0.00
PCRX cash_flow (annual, 2022-12-31) — Income Tax Paid Supplemental Data: 7398000.00
PCRX balance_sheet (annual, 2022-12-31) — Income Tax Payable: 0.00
PCRX income_statement (annual, 2022-12-31) — Interest Expense: 35576000.00
PCRX income_statement (annual, 2022-12-31) — Interest Expense Non Operating: 35576000.00
PCRX income_statement (annual, 2022-12-31) — Interest Income: 4542000.00
PCRX income_statement (annual, 2022-12-31) — Interest Income Non Operating: 4542000.00
PCRX cash_flow (annual, 2022-12-31) — Interest Paid Supplemental Data: 33295000.00
PCRX balance_sheet (annual, 2022-12-31) — Interest Payable: 8941000.00
PCRX balance_sheet (annual, 2022-12-31) — Inventory: 96063000.00
PCRX balance_sheet (annual, 2022-12-31) — Invested Capital: 1464481000.00
PCRX cash_flow (annual, 2022-12-31) — Investing Cash Flow: -225185000.00
PCRX balance_sheet (annual, 2022-12-31) — Investmentin Financial Assets: 37209000.00
PCRX balance_sheet (annual, 2022-12-31) — Investments And Advances: 37209000.00
PCRX cash_flow (annual, 2022-12-31) — Issuance Of Debt: 0.00
PCRX balance_sheet (annual, 2022-12-31) — Leases: 61302000.00
PCRX balance_sheet (annual, 2022-12-31) — Long Term Capital Lease Obligation: 64802000.00
PCRX balance_sheet (annual, 2022-12-31) — Long Term Debt: 655823000.00
PCRX balance_sheet (annual, 2022-12-31) — Long Term Debt And Capital Lease Obligation: 720625000.00
PCRX cash_flow (annual, 2022-12-31) — Long Term Debt Issuance: 0.00
PCRX cash_flow (annual, 2022-12-31) — Long Term Debt Payments: -427694000.00
PCRX balance_sheet (annual, 2022-12-31) — Machinery Furniture Equipment: 136464000.00
PCRX cash_flow (annual, 2022-12-31) — Net Business Purchase And Sale: -32000000.00
PCRX cash_flow (annual, 2022-12-31) — Net Common Stock Issuance: 0.00
PCRX balance_sheet (annual, 2022-12-31) — Net Debt: 585332000.00
PCRX income_statement (annual, 2022-12-31) — Net Income: 15909000.00
PCRX income_statement (annual, 2022-12-31) — Net Income Common Stockholders: 15909000.00
PCRX income_statement (annual, 2022-12-31) — Net Income Continuous Operations: 15909000.00
PCRX income_statement (annual, 2022-12-31) — Net Income From Continuing And Discontinued Operation: 15909000.00
PCRX income_statement (annual, 2022-12-31) — Net Income From Continuing Operation Net Minority Interest: 15909000.00
PCRX cash_flow (annual, 2022-12-31) — Net Income From Continuing Operations: 15909000.00
PCRX income_statement (annual, 2022-12-31) — Net Income Including Noncontrolling Interests: 15909000.00
PCRX income_statement (annual, 2022-12-31) — Net Interest Income: -35434000.00
PCRX cash_flow (annual, 2022-12-31) — Net Investment Purchase And Sale: -163109000.00
PCRX cash_flow (annual, 2022-12-31) — Net Issuance Payments Of Debt: -427694000.00
PCRX cash_flow (annual, 2022-12-31) — Net Long Term Debt Issuance: -427694000.00
PCRX income_statement (annual, 2022-12-31) — Net Non Operating Interest Income Expense: -35434000.00
PCRX cash_flow (annual, 2022-12-31) — Net Other Financing Charges: -1175000.00
PCRX cash_flow (annual, 2022-12-31) — Net Other Investing Changes: -32000000.00
PCRX balance_sheet (annual, 2022-12-31) — Net PPE: 254389000.00
PCRX cash_flow (annual, 2022-12-31) — Net PPE Purchase And Sale: -30076000.00
PCRX balance_sheet (annual, 2022-12-31) — Net Tangible Assets: 71221000.00
PCRX balance_sheet (annual, 2022-12-31) — Non Current Deferred Assets: 160309000.00
PCRX balance_sheet (annual, 2022-12-31) — Non Current Deferred Taxes Assets: 160309000.00
PCRX income_statement (annual, 2022-12-31) — Normalized EBITDA: 140379000.00
PCRX income_statement (annual, 2022-12-31) — Normalized Income: 15909000.00
PCRX cash_flow (annual, 2022-12-31) — Operating Cash Flow: 145274000.00
PCRX cash_flow (annual, 2022-12-31) — Operating Gains Losses: 285000.00
PCRX income_statement (annual, 2022-12-31) — Operating Income: 60024000.00
PCRX income_statement (annual, 2022-12-31) — Operating Revenue: 666823000.00
PCRX balance_sheet (annual, 2022-12-31) — Ordinary Shares Number: 45927790.00
PCRX balance_sheet (annual, 2022-12-31) — Other Current Assets: 15223000.00
PCRX balance_sheet (annual, 2022-12-31) — Other Current Borrowings: 33648000.00
PCRX balance_sheet (annual, 2022-12-31) — Other Equity Adjustments: -380000.00
PCRX income_statement (annual, 2022-12-31) — Other Gand A: 73989000.00
PCRX income_statement (annual, 2022-12-31) — Other Income Expense: -11288000.00
PCRX balance_sheet (annual, 2022-12-31) — Other Intangible Assets: 540546000.00
PCRX balance_sheet (annual, 2022-12-31) — Other Investments: 27170000.00
PCRX cash_flow (annual, 2022-12-31) — Other Non Cash Items: -21984000.00
PCRX balance_sheet (annual, 2022-12-31) — Other Non Current Assets: 27170000.00
PCRX balance_sheet (annual, 2022-12-31) — Other Non Current Liabilities: 37791000.00
PCRX income_statement (annual, 2022-12-31) — Other Non Operating Income Expenses: -11288000.00
PCRX income_statement (annual, 2022-12-31) — Other Operating Expenses: 10903000.00
PCRX balance_sheet (annual, 2022-12-31) — Other Properties: 70877000.00
PCRX balance_sheet (annual, 2022-12-31) — Other Short Term Investments: 184512000.00
PCRX balance_sheet (annual, 2022-12-31) — Payables: 15220000.00
PCRX balance_sheet (annual, 2022-12-31) — Payables And Accrued Expenses: 78807000.00
PCRX balance_sheet (annual, 2022-12-31) — Pensionand Other Post Retirement Benefit Plans Current: 26198000.00
PCRX balance_sheet (annual, 2022-12-31) — Preferred Stock: 0.00
PCRX income_statement (annual, 2022-12-31) — Pretax Income: 13302000.00
PCRX cash_flow (annual, 2022-12-31) — Proceeds From Stock Option Exercised: 27341000.00
PCRX balance_sheet (annual, 2022-12-31) — Properties: 0.00
PCRX cash_flow (annual, 2022-12-31) — Purchase Of Business: -32000000.00
PCRX cash_flow (annual, 2022-12-31) — Purchase Of Investment: -400685000.00
PCRX cash_flow (annual, 2022-12-31) — Purchase Of PPE: -30076000.00
PCRX balance_sheet (annual, 2022-12-31) — Raw Materials: 39810000.00
PCRX balance_sheet (annual, 2022-12-31) — Receivables: 98397000.00
PCRX income_statement (annual, 2022-12-31) — Reconciled Cost Of Revenue: 165082000.00
PCRX income_statement (annual, 2022-12-31) — Reconciled Depreciation: 91501000.00
PCRX cash_flow (annual, 2022-12-31) — Repayment Of Debt: -427694000.00
PCRX cash_flow (annual, 2022-12-31) — Repurchase Of Capital Stock: 0.00
PCRX income_statement (annual, 2022-12-31) — Research And Development: 84797000.00
PCRX income_statement (annual, 2022-12-31) — Restructuring And Mergern Acquisition: 10903000.00
PCRX balance_sheet (annual, 2022-12-31) — Retained Earnings: -148751000.00
PCRX income_statement (annual, 2022-12-31) — Salaries And Wages: 35531000.00
PCRX cash_flow (annual, 2022-12-31) — Sale Of Investment: 237576000.00
PCRX income_statement (annual, 2022-12-31) — Selling And Marketing Expense: 144996000.00
PCRX income_statement (annual, 2022-12-31) — Selling General And Administration: 254516000.00
PCRX balance_sheet (annual, 2022-12-31) — Share Issued: 45927790.00
PCRX income_statement (annual, 2022-12-31) — Special Income Charges: 0.00
PCRX cash_flow (annual, 2022-12-31) — Stock Based Compensation: 48092000.00
PCRX balance_sheet (annual, 2022-12-31) — Stockholders Equity: 775010000.00
PCRX balance_sheet (annual, 2022-12-31) — Tangible Book Value: 71221000.00
PCRX income_statement (annual, 2022-12-31) — Tax Effect Of Unusual Items: 0.00
PCRX income_statement (annual, 2022-12-31) — Tax Provision: -2607000.00
PCRX income_statement (annual, 2022-12-31) — Tax Rate For Calcs: 0.21
PCRX balance_sheet (annual, 2022-12-31) — Total Assets: 1681200000.00
PCRX balance_sheet (annual, 2022-12-31) — Total Capitalization: 1430833000.00
PCRX balance_sheet (annual, 2022-12-31) — Total Debt: 763394000.00
PCRX balance_sheet (annual, 2022-12-31) — Total Equity Gross Minority Interest: 775010000.00
PCRX income_statement (annual, 2022-12-31) — Total Expenses: 606799000.00
PCRX balance_sheet (annual, 2022-12-31) — Total Liabilities Net Minority Interest: 906190000.00
PCRX balance_sheet (annual, 2022-12-31) — Total Non Current Assets: 1182866000.00
PCRX balance_sheet (annual, 2022-12-31) — Total Non Current Liabilities Net Minority Interest: 758416000.00
PCRX income_statement (annual, 2022-12-31) — Total Operating Income As Reported: 60024000.00
PCRX income_statement (annual, 2022-12-31) — Total Other Finance Cost: 4400000.00
PCRX balance_sheet (annual, 2022-12-31) — Total Tax Payable: 0.00
PCRX income_statement (annual, 2022-12-31) — Total Unusual Items: 0.00
PCRX income_statement (annual, 2022-12-31) — Total Unusual Items Excluding Goodwill: 0.00
PCRX balance_sheet (annual, 2022-12-31) — Work In Process: 28853000.00
PCRX balance_sheet (annual, 2022-12-31) — Working Capital: 350560000.00
PCRX income_statement (annual, 2023-12-31) — +Operating Expense: 402634000.00
PCRX income_statement (annual, 2023-12-31) — +Total Revenue: 674978000.00
PCRX balance_sheet (annual, 2023-12-31) — Accounts Payable: 15698000.00
PCRX balance_sheet (annual, 2023-12-31) — Accounts Receivable: 105556000.00
PCRX balance_sheet (annual, 2023-12-31) — Accumulated Depreciation: -135306000.00
PCRX balance_sheet (annual, 2023-12-31) — Additional Paid In Capital: 976633000.00
PCRX income_statement (annual, 2023-12-31) — Amortization: 57288000.00
PCRX income_statement (annual, 2023-12-31) — Amortization Of Intangibles Income Statement: 57288000.00
PCRX cash_flow (annual, 2023-12-31) — Asset Impairment Charge: 0.00
PCRX balance_sheet (annual, 2023-12-31) — Available For Sale Securities: 2410000.00
PCRX income_statement (annual, 2023-12-31) — Average Dilution Earnings: 4114000.00
PCRX income_statement (annual, 2023-12-31) — Basic Average Shares: 46222000.00
PCRX income_statement (annual, 2023-12-31) — Basic EPS: 0.91
PCRX cash_flow (annual, 2023-12-31) — Beginning Cash Position: 104139000.00
PCRX cash_flow (annual, 2023-12-31) — Capital Expenditure: -15161000.00
PCRX balance_sheet (annual, 2023-12-31) — Capital Lease Obligations: 63607000.00
PCRX balance_sheet (annual, 2023-12-31) — Capital Stock: 46000.00
PCRX balance_sheet (annual, 2023-12-31) — Cash And Cash Equivalents: 153298000.00
PCRX balance_sheet (annual, 2023-12-31) — Cash Cash Equivalents And Short Term Investments: 278581000.00
PCRX cash_flow (annual, 2023-12-31) — Cash Flow From Continuing Financing Activities: -183031000.00
PCRX cash_flow (annual, 2023-12-31) — Cash Flow From Continuing Investing Activities: 77541000.00
PCRX cash_flow (annual, 2023-12-31) — Cash Flow From Continuing Operating Activities: 154649000.00
PCRX cash_flow (annual, 2023-12-31) — Change In Account Payable: 916000.00
PCRX cash_flow (annual, 2023-12-31) — Change In Accrued Expense: -21605000.00
PCRX cash_flow (annual, 2023-12-31) — Change In Inventory: -8290000.00
PCRX cash_flow (annual, 2023-12-31) — Change In Other Current Liabilities: 434000.00
PCRX cash_flow (annual, 2023-12-31) — Change In Payable: 916000.00
PCRX cash_flow (annual, 2023-12-31) — Change In Payables And Accrued Expense: -20689000.00
PCRX cash_flow (annual, 2023-12-31) — Change In Prepaid Assets: -5063000.00
PCRX cash_flow (annual, 2023-12-31) — Change In Receivables: -7159000.00
PCRX cash_flow (annual, 2023-12-31) — Change In Working Capital: -41201000.00
PCRX cash_flow (annual, 2023-12-31) — Changes In Account Receivables: -7159000.00
PCRX cash_flow (annual, 2023-12-31) — Changes In Cash: 49159000.00
PCRX balance_sheet (annual, 2023-12-31) — Common Stock: 46000.00
PCRX balance_sheet (annual, 2023-12-31) — Common Stock Equity: 870130000.00
PCRX cash_flow (annual, 2023-12-31) — Common Stock Payments: 0.00
PCRX balance_sheet (annual, 2023-12-31) — Construction In Progress: 105905000.00
PCRX income_statement (annual, 2023-12-31) — Cost Of Revenue: 184669000.00
PCRX balance_sheet (annual, 2023-12-31) — Current Accrued Expenses: 42561000.00
PCRX balance_sheet (annual, 2023-12-31) — Current Assets: 509994000.00
PCRX balance_sheet (annual, 2023-12-31) — Current Capital Lease Obligation: 8801000.00
PCRX balance_sheet (annual, 2023-12-31) — Current Debt: 8641000.00
PCRX balance_sheet (annual, 2023-12-31) — Current Debt And Capital Lease Obligation: 17442000.00
PCRX balance_sheet (annual, 2023-12-31) — Current Liabilities: 97383000.00
PCRX cash_flow (annual, 2023-12-31) — Deferred Income Tax: 15615000.00
PCRX cash_flow (annual, 2023-12-31) — Deferred Tax: 15615000.00
PCRX cash_flow (annual, 2023-12-31) — Depreciation Amortization Depletion: 75574000.00
PCRX income_statement (annual, 2023-12-31) — Depreciation Amortization Depletion Income Statement: 57288000.00
PCRX cash_flow (annual, 2023-12-31) — Depreciation And Amortization: 75574000.00
PCRX income_statement (annual, 2023-12-31) — Depreciation And Amortization In Income Statement: 57288000.00
PCRX income_statement (annual, 2023-12-31) — Diluted Average Shares: 51979000.00
PCRX income_statement (annual, 2023-12-31) — Diluted EPS: 0.89
PCRX income_statement (annual, 2023-12-31) — Diluted NI Availto Com Stockholders: 46069000.00
PCRX income_statement (annual, 2023-12-31) — EBIT: 79011000.00
PCRX income_statement (annual, 2023-12-31) — EBITDA: 154585000.00
PCRX cash_flow (annual, 2023-12-31) — Effect Of Exchange Rate Changes: 0.00
PCRX cash_flow (annual, 2023-12-31) — End Cash Position: 153298000.00
PCRX cash_flow (annual, 2023-12-31) — Financing Cash Flow: -183031000.00
PCRX balance_sheet (annual, 2023-12-31) — Finished Goods: 19039000.00
PCRX cash_flow (annual, 2023-12-31) — Free Cash Flow: 139488000.00
PCRX balance_sheet (annual, 2023-12-31) — Gains Losses Not Affecting Retained Earnings: 247000.00
PCRX income_statement (annual, 2023-12-31) — General And Administrative Expense: 116401000.00
PCRX balance_sheet (annual, 2023-12-31) — Goodwill: 163243000.00
PCRX balance_sheet (annual, 2023-12-31) — Goodwill And Other Intangible Assets: 646501000.00
PCRX balance_sheet (annual, 2023-12-31) — Gross PPE: 370253000.00
PCRX income_statement (annual, 2023-12-31) — Gross Profit: 490309000.00
PCRX income_statement (annual, 2023-12-31) — Impairment Of Capital Assets: 0.00
PCRX cash_flow (annual, 2023-12-31) — Income Tax Paid Supplemental Data: 4366000.00
PCRX income_statement (annual, 2023-12-31) — Interest Expense: 17310000.00
PCRX income_statement (annual, 2023-12-31) — Interest Expense Non Operating: 17310000.00
PCRX income_statement (annual, 2023-12-31) — Interest Income: 11444000.00
PCRX income_statement (annual, 2023-12-31) — Interest Income Non Operating: 11444000.00
PCRX cash_flow (annual, 2023-12-31) — Interest Paid Supplemental Data: 27635000.00
PCRX balance_sheet (annual, 2023-12-31) — Interest Payable: 1389000.00
PCRX balance_sheet (annual, 2023-12-31) — Inventory: 104353000.00
PCRX balance_sheet (annual, 2023-12-31) — Invested Capital: 1392567000.00
PCRX cash_flow (annual, 2023-12-31) — Investing Cash Flow: 77541000.00
PCRX balance_sheet (annual, 2023-12-31) — Investmentin Financial Assets: 2410000.00
PCRX balance_sheet (annual, 2023-12-31) — Investments And Advances: 2410000.00
PCRX cash_flow (annual, 2023-12-31) — Issuance Of Debt: 149550000.00
PCRX balance_sheet (annual, 2023-12-31) — Leases: 61826000.00
PCRX balance_sheet (annual, 2023-12-31) — Long Term Capital Lease Obligation: 54806000.00
PCRX balance_sheet (annual, 2023-12-31) — Long Term Debt: 513796000.00
PCRX balance_sheet (annual, 2023-12-31) — Long Term Debt And Capital Lease Obligation: 568602000.00
PCRX cash_flow (annual, 2023-12-31) — Long Term Debt Issuance: 149550000.00
PCRX cash_flow (annual, 2023-12-31) — Long Term Debt Payments: -330312000.00
PCRX balance_sheet (annual, 2023-12-31) — Machinery Furniture Equipment: 141502000.00
PCRX cash_flow (annual, 2023-12-31) — Net Business Purchase And Sale: 0.00
PCRX cash_flow (annual, 2023-12-31) — Net Common Stock Issuance: 0.00
PCRX balance_sheet (annual, 2023-12-31) — Net Debt: 369139000.00
PCRX income_statement (annual, 2023-12-31) — Net Income: 41955000.00
PCRX income_statement (annual, 2023-12-31) — Net Income Common Stockholders: 41955000.00
PCRX income_statement (annual, 2023-12-31) — Net Income Continuous Operations: 41955000.00
PCRX income_statement (annual, 2023-12-31) — Net Income From Continuing And Discontinued Operation: 41955000.00
PCRX income_statement (annual, 2023-12-31) — Net Income From Continuing Operation Net Minority Interest: 41955000.00
PCRX cash_flow (annual, 2023-12-31) — Net Income From Continuing Operations: 41955000.00
PCRX income_statement (annual, 2023-12-31) — Net Income Including Noncontrolling Interests: 41955000.00
PCRX income_statement (annual, 2023-12-31) — Net Interest Income: -8862000.00
PCRX cash_flow (annual, 2023-12-31) — Net Investment Purchase And Sale: 92702000.00
PCRX cash_flow (annual, 2023-12-31) — Net Issuance Payments Of Debt: -180762000.00
PCRX cash_flow (annual, 2023-12-31) — Net Long Term Debt Issuance: -180762000.00
PCRX income_statement (annual, 2023-12-31) — Net Non Operating Interest Income Expense: -8862000.00
PCRX cash_flow (annual, 2023-12-31) — Net Other Financing Charges: -7019000.00
PCRX balance_sheet (annual, 2023-12-31) — Net PPE: 234947000.00
PCRX cash_flow (annual, 2023-12-31) — Net PPE Purchase And Sale: -15161000.00
PCRX balance_sheet (annual, 2023-12-31) — Net Tangible Assets: 223629000.00
PCRX balance_sheet (annual, 2023-12-31) — Non Current Deferred Assets: 144485000.00
PCRX balance_sheet (annual, 2023-12-31) — Non Current Deferred Taxes Assets: 144485000.00
PCRX income_statement (annual, 2023-12-31) — Normalized EBITDA: 171511000.00
PCRX income_statement (annual, 2023-12-31) — Normalized Income: 53464680.00
PCRX cash_flow (annual, 2023-12-31) — Operating Cash Flow: 154649000.00
PCRX cash_flow (annual, 2023-12-31) — Operating Gains Losses: 16926000.00
PCRX income_statement (annual, 2023-12-31) — Operating Income: 87675000.00
PCRX income_statement (annual, 2023-12-31) — Operating Revenue: 674978000.00
PCRX balance_sheet (annual, 2023-12-31) — Ordinary Shares Number: 46481174.00
PCRX balance_sheet (annual, 2023-12-31) — Other Current Assets: 21504000.00
PCRX balance_sheet (annual, 2023-12-31) — Other Current Borrowings: 8641000.00
PCRX balance_sheet (annual, 2023-12-31) — Other Equity Adjustments: 247000.00
PCRX income_statement (annual, 2023-12-31) — Other Gand A: 82737000.00
PCRX income_statement (annual, 2023-12-31) — Other Income Expense: -17112000.00
PCRX balance_sheet (annual, 2023-12-31) — Other Intangible Assets: 483258000.00
PCRX cash_flow (annual, 2023-12-31) — Other Non Cash Items: -2115000.00
PCRX balance_sheet (annual, 2023-12-31) — Other Non Current Assets: 36049000.00
PCRX balance_sheet (annual, 2023-12-31) — Other Non Current Liabilities: 38271000.00
PCRX income_statement (annual, 2023-12-31) — Other Non Operating Income Expenses: -186000.00
PCRX income_statement (annual, 2023-12-31) — Other Operating Expenses: -352000.00
PCRX balance_sheet (annual, 2023-12-31) — Other Properties: 61020000.00
PCRX balance_sheet (annual, 2023-12-31) — Other Short Term Investments: 125283000.00
PCRX income_statement (annual, 2023-12-31) — Other Special Charges: 16926000.00
PCRX balance_sheet (annual, 2023-12-31) — Payables: 15698000.00
PCRX balance_sheet (annual, 2023-12-31) — Payables And Accrued Expenses: 58259000.00
PCRX balance_sheet (annual, 2023-12-31) — Pensionand Other Post Retirement Benefit Plans Current: 21682000.00
PCRX balance_sheet (annual, 2023-12-31) — Preferred Stock: 0.00
PCRX income_statement (annual, 2023-12-31) — Pretax Income: 61701000.00
PCRX cash_flow (annual, 2023-12-31) — Proceeds From Stock Option Exercised: 4750000.00
PCRX balance_sheet (annual, 2023-12-31) — Properties: 0.00
PCRX cash_flow (annual, 2023-12-31) — Purchase Of Business: 0.00
PCRX cash_flow (annual, 2023-12-31) — Purchase Of Investment: -144366000.00
PCRX cash_flow (annual, 2023-12-31) — Purchase Of PPE: -15161000.00
PCRX balance_sheet (annual, 2023-12-31) — Raw Materials: 54099000.00
PCRX balance_sheet (annual, 2023-12-31) — Receivables: 105556000.00
PCRX income_statement (annual, 2023-12-31) — Reconciled Cost Of Revenue: 166383000.00
PCRX income_statement (annual, 2023-12-31) — Reconciled Depreciation: 75574000.00
PCRX cash_flow (annual, 2023-12-31) — Repayment Of Debt: -330312000.00
PCRX cash_flow (annual, 2023-12-31) — Repurchase Of Capital Stock: 0.00
PCRX income_statement (annual, 2023-12-31) — Research And Development: 76257000.00
PCRX income_statement (annual, 2023-12-31) — Restructuring And Mergern Acquisition: -352000.00
PCRX balance_sheet (annual, 2023-12-31) — Retained Earnings: -106796000.00
PCRX income_statement (annual, 2023-12-31) — Salaries And Wages: 33664000.00
PCRX cash_flow (annual, 2023-12-31) — Sale Of Investment: 237068000.00
PCRX income_statement (annual, 2023-12-31) — Selling And Marketing Expense: 153040000.00
PCRX income_statement (annual, 2023-12-31) — Selling General And Administration: 269441000.00
PCRX balance_sheet (annual, 2023-12-31) — Share Issued: 46481174.00
PCRX income_statement (annual, 2023-12-31) — Special Income Charges: -16926000.00
PCRX cash_flow (annual, 2023-12-31) — Stock Based Compensation: 47895000.00
PCRX balance_sheet (annual, 2023-12-31) — Stockholders Equity: 870130000.00
PCRX balance_sheet (annual, 2023-12-31) — Tangible Book Value: 223629000.00
PCRX income_statement (annual, 2023-12-31) — Tax Effect Of Unusual Items: -5416320.00
PCRX income_statement (annual, 2023-12-31) — Tax Provision: 19746000.00
PCRX income_statement (annual, 2023-12-31) — Tax Rate For Calcs: 0.32
PCRX balance_sheet (annual, 2023-12-31) — Total Assets: 1574386000.00
PCRX balance_sheet (annual, 2023-12-31) — Total Capitalization: 1383926000.00
PCRX balance_sheet (annual, 2023-12-31) — Total Debt: 586044000.00
PCRX balance_sheet (annual, 2023-12-31) — Total Equity Gross Minority Interest: 870130000.00
PCRX income_statement (annual, 2023-12-31) — Total Expenses: 587303000.00
PCRX balance_sheet (annual, 2023-12-31) — Total Liabilities Net Minority Interest: 704256000.00
PCRX balance_sheet (annual, 2023-12-31) — Total Non Current Assets: 1064392000.00
PCRX balance_sheet (annual, 2023-12-31) — Total Non Current Liabilities Net Minority Interest: 606873000.00
PCRX income_statement (annual, 2023-12-31) — Total Operating Income As Reported: 87675000.00
PCRX income_statement (annual, 2023-12-31) — Total Other Finance Cost: 2996000.00
PCRX income_statement (annual, 2023-12-31) — Total Unusual Items: -16926000.00
PCRX income_statement (annual, 2023-12-31) — Total Unusual Items Excluding Goodwill: -16926000.00
PCRX balance_sheet (annual, 2023-12-31) — Treasury Stock: 0.00
PCRX balance_sheet (annual, 2023-12-31) — Work In Process: 31215000.00
PCRX balance_sheet (annual, 2023-12-31) — Working Capital: 412611000.00
PCRX cash_flow (quarterly, 2024-09-30) — Asset Impairment Charge: 163243000.00
PCRX income_statement (quarterly, 2024-09-30) — Average Dilution Earnings: 0.00
PCRX balance_sheet (quarterly, 2024-09-30) — Current Debt: 201466000.00
PCRX income_statement (quarterly, 2024-09-30) — Impairment Of Capital Assets: 163243000.00
PCRX balance_sheet (quarterly, 2024-09-30) — Investmentin Financial Assets: 0.00
PCRX balance_sheet (quarterly, 2024-09-30) — Investments And Advances: 36726000.00
PCRX cash_flow (quarterly, 2024-09-30) — Issuance Of Debt: 0.00
PCRX cash_flow (quarterly, 2024-09-30) — Long Term Debt Issuance: 0.00
PCRX cash_flow (quarterly, 2024-09-30) — Operating Gains Losses: 0.00
PCRX balance_sheet (quarterly, 2024-09-30) — Other Current Borrowings: 201466000.00
PCRX balance_sheet (quarterly, 2024-09-30) — Other Investments: 36726000.00
PCRX income_statement (annual, 2024-12-31) — +Operating Expense: 440666000.00
PCRX income_statement (annual, 2024-12-31) — +Total Revenue: 700966000.00
PCRX balance_sheet (annual, 2024-12-31) — Accounts Payable: 19133000.00
PCRX balance_sheet (annual, 2024-12-31) — Accounts Receivable: 113304000.00
PCRX balance_sheet (annual, 2024-12-31) — Accumulated Depreciation: -132929000.00
PCRX balance_sheet (annual, 2024-12-31) — Additional Paid In Capital: 1009435000.00
PCRX income_statement (annual, 2024-12-31) — Amortization: 57288000.00
PCRX income_statement (annual, 2024-12-31) — Amortization Of Intangibles Income Statement: 57288000.00
PCRX cash_flow (annual, 2024-12-31) — Asset Impairment Charge: 163243000.00
PCRX cash_flow (quarterly, 2024-12-31) — Asset Impairment Charge: 0.00
PCRX income_statement (annual, 2024-12-31) — Average Dilution Earnings: 0.00
PCRX income_statement (quarterly, 2024-12-31) — Average Dilution Earnings: 0.00
PCRX income_statement (annual, 2024-12-31) — Basic Average Shares: 46245000.00
PCRX income_statement (annual, 2024-12-31) — Basic EPS: -2.15
PCRX cash_flow (annual, 2024-12-31) — Beginning Cash Position: 153298000.00
PCRX cash_flow (annual, 2024-12-31) — Capital Expenditure: -10636000.00
PCRX balance_sheet (annual, 2024-12-31) — Capital Lease Obligations: 53532000.00
PCRX balance_sheet (annual, 2024-12-31) — Capital Stock: 47000.00
PCRX balance_sheet (annual, 2024-12-31) — Cash And Cash Equivalents: 276774000.00